StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms ...Middle East

PR Newswire - News
StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms

BALDWIN PARK, Calif., Dec. 19, 2024 /PRNewswire/ -- StemCyte announced a significant breakthrough in its Phase IIa clinical trial of HPC, Cord Blood (HPC, CB) for treating Post-COVID Syndrome (Long COVID). This trial results demonstrated that cord blood significantly improved fatigue...

    Read More Details
    Finally We wish PressBee provided you with enough information of ( StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms )

    Apple Storegoogle play

    Also on site :



    Latest News